If your dog appears lethargic, skips meals, or lacks energy, it may not be temporary. Anemia, a condition where the dog lacks enough healthy red blood cells to transport oxygen to its tissues, is a ...

Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...

The pathophysiology of warm autoimmune hemolytic anemia (AIHA) is based on more than isolated red blood cell (RBC) destruction. Several complex biological mechanisms and signaling disruptions within ...

Paris, February 9, 2026. The US Food and Drug Administration (FDA) has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) ...

Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi ...

(IN BRIEF) Sanofi has received Breakthrough Therapy designation from the U.S. FDA and orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for rilzabrutinib (Wayrilz) in warm ...

Like many autoimmune conditions, researchers do not know the exact trigger causing these autoantibodies to target healthy RBCs. These cases are classified as primary or idiopathic warm AIHA. In other ...

1. In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete response in eleven patients with autoimmune hemolytic anemia who had ...

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 /PRNewswire/ -- Ouro Medicines, a clinical stage biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated ...

CAR T-cell therapies are now being used to treat patients with B-cell driven autoimmune diseases such as lupus. Another such condition is autoimmune hemolytic anemia, in which immune cells destroy red ...